Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?

Abstract Multiple sclerosis (MS) more than any other neurological disorder has experienced a tremendous progress in available evidence-based innovator disease modifying therapies (DMT). These medications include injectable complex nonbiological drugs (CNBD), the injectable biological products β-inte...

Full description

Bibliographic Details
Main Author: Victor M. Rivera
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-07-01
Series:Neurology and Therapy
Subjects:
Bioequivalence
Biosimilar medications
Efficacy and safety
Licensing and regulation
Molecular differences
Multiple sclerosis
Online Access:http://link.springer.com/article/10.1007/s40120-019-0145-0

Internet

http://link.springer.com/article/10.1007/s40120-019-0145-0

Similar Items